Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline

CompoSecure

Viant Technology

Granite Ridge Resources Inc

SNDL Inc.

SoFi Technologies

VistaGen Therapeutics

If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.

7 Stocks Under $15 Predicted to Boom in the Next 2 Years

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Puma Biotech (PBYI) closed the most recent trading day at $5.49, moving -0.63% from the previous trading session.

Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts

Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?

LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Repligen

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Puma Biotech (PBYI) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?

PBYI vs. RGEN: Which Stock Is the Better Value Option?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term

Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.

Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released it's fourth quarter and full year 2023 earnings and will host a conference call to discuss operating results and outlook.

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Does Puma Biotech (PBYI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should Know

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Editas Medicine

Exelixis

Immunocore Holdings

Sarepta Therapeutics

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

5 Biotech Stocks to Consider for Your Portfolio in 2024

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that it had initiated ALISCA-Lung1, a Phase II clinical trial of alisertib in small cell lung cancer.

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Puma Biotech (PBYI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?

Amgen

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Amgen (AMGN). But which of these two stocks offers value investors a better bang for their buck right now?

PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?

Amylyx Pharmaceuticals

Cassava Sciences Inc

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

3 small-cap biotechs with potential breakthroughs in 2024

Gigacloud Tech

Netflix

Oceaneering

Here are four top-performing liquid stocks, Netflix (NFLX), Oceaneering International (OII), Puma Biotechnology (PBYI) and GigaCloud (GCT) which investors can add to their portfolio to boost returns.

4 Top-Performing Liquid Stocks to Strengthen Your Portfolio

Dynagas LNG Partners LP

Iteris

Penny stocks are generally defined as stocks that trade for less than $5 per share. Low-priced stocks appeal to investors who can wait for these stock prices to appreciate.

3 Strong Buy Stocks Under $5: January 2024

Nomura Holdings

Navigator Hlds

Universal Technical Institute

Universal Technical Institute (UTI), Puma Biotechnology (PBYI), Nomura (NMR) and Navigator Holdings (NVGS) have been selected as the breakout stocks for today.

4 Best Breakout Stocks to Buy for Superlative Returns

Vertex Pharmaceuticals

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value investors a better bang for their buck right now?

PBYI or VRTX: Which Is the Better Value Stock Right Now?

Puma Biotech (PBYI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

News for Puma Biotechnology Stock (PBYI)